the Chongqing Primary Aldosteronism Study (CONPASS) Group Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2020
NCT04461535
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

the Chongqing Primary Aldosteronism Study (CONPASS) Group